GLORIA PHARMA.(SZ:002437) Xin Lang Zheng Quan·2025-11-14 02:20Core Viewpoint - Yuheng Pharmaceutical's stock has shown a significant increase this year, with a 40.96% rise, despite recent fluctuations in trading volume and net capital outflow [1][2]. Financial Performance - For the period from January to September 2025, Yuheng Pharmaceutical reported a revenue of 1.665 billion yuan, a year-on-year decrease of 10.36%. However, the net profit attributable to shareholders increased by 32.85% to 244 million yuan [2]. - The company has distributed a total of 692 million yuan in dividends since its A-share listing, with no dividends paid in the last three years [3]. Stock Market Activity - As of November 14, Yuheng Pharmaceutical's stock price was 3.51 yuan per share, with a market capitalization of 7.883 billion yuan. The stock experienced a 2.03% increase during the trading session [1]. - The trading volume indicated a net outflow of 5.7995 million yuan from major funds, with significant buying and selling activity from large orders [1]. Shareholder Information - As of November 10, the number of shareholders for Yuheng Pharmaceutical was 104,800, a decrease of 0.66% from the previous period. The average number of circulating shares per person increased by 0.85% to 20,038 shares [2]. - The second-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 66.3697 million shares, an increase of 35.1366 million shares from the previous period [3]. Business Overview - Yuheng Pharmaceutical, established on March 27, 2000, and listed on June 23, 2010, is primarily engaged in the production and sales of pharmaceuticals. Its main revenue sources include vitamin drugs (43.88%), cardiovascular drugs (28.00%), and orthopedic drugs (10.72%) [1].